For the quarter ending 2026-03-31, TOVX had $1,374K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,044 | -1,996 | -4,361 | -17,382 |
| Stock-based compensation | 135 | 153 | 228 | 273 |
| Change in fair value of contingent consideration | 27 | -775 | 633 | 9,173 |
| Loss on asset disposal | - | 1 | - | - |
| Non-cash lease expense | 143 | 139 | 134 | 249 |
| Depreciation | 24 | 27 | 28 | 53 |
| Deferred research and development tax credit | -417 | 1,118 | -455 | -851 |
| Prepaid expenses and other current assets | -428 | 410 | -251 | -615 |
| Accounts payable | -397 | 209 | 161 | -301 |
| Accrued expenses | -27 | -891 | -784 | -602 |
| Accrued employee benefits | -172 | -308 | -9 | -427 |
| Payment of contingent consideration | - | -500 | -500 | - |
| Operating lease liability | -156 | -149 | -145 | -268 |
| Proceeds from issuance common stock and warrants offering, net of issuance costs | - | 6,690 | - | - |
| Net cash used in operating activities | -2,456 | -2,882 | -4,319 | -9,468 |
| Proceeds from warrant inducement | - | 3,942 | - | - |
| Purchases of property and equipment | - | 0 | 19 | 16 |
| Proceeds from long term debt | - | 15 | 34 | 1,458 |
| Net cash used in investing activities | - | 0 | -19 | -16 |
| Proceeds from issuance of common stock | - | - | 0 | 6,690 |
| Proceeds from issuance of common stock for warrant exercises | - | 0 | 0 | 4 |
| Tax credit receivable | 1,612 | -1,552 | 41 | 1,798 |
| Payment of loans payable | -49 | -1 | -2 | -67 |
| Proceeds from issuance under at - the - market offering, net of issuance cost | 2,303 | 6,554 | 279 | - |
| Net cash provided by financing activities | 3,866 | 8,458 | -148 | 9,883 |
| Effects of exchange rate changes on cash and cash equivalents | -36 | -48 | -106 | 62 |
| Net decrease in cash and cash equivalents and restricted cash | 1,374 | 5,528 | -4,592 | 461 |
| Cash and cash equivalents and restricted at the beginning of this period | 13,102 | 7,574 | 11,705 | - |
| Cash and cash equivalents and restricted cash at the end of this period | 14,476 | 13,102 | 7,574 | - |
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)